High expression of minichromosome maintenance protein 6 in classic Hodgkin's lymphoma points to a cell cycle arrest in G1 phase

Archives of Iranian Medicine

Volumn 11, Issue 5, 2008, Pages 532-538

  Karimi, Shirin ^a   Mohammadi, Forouzan ^a   Khodadad, Kian ^a   Emami, Habib ^a   Seyfollahi, Leila ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cell cycle; Cell proliferation; Hodgkin's lymphoma; Ki 67; MCM6

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 6; MONOCLONAL ANTIBODY; PARAFFIN;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; PROTEIN EXPRESSION; REED STERNBERG CELL; SYMPTOM; THORAX WALL; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; REED-STERNBERG CELLS; YOUNG ADULT;

EID: 63449102400     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fujita M, Kiyono T, Hayashi Y, Ishibashi M. In vivo interaction of human MCM heterohexameric complexes with chromatin. Possible involvement of ATP. J Biol Chem. 1997; 272: 10928-10935.
2. Ogawa Y, Takahashi T, Masukata H. Association of fission yeast Orp1 and MCM6 proteins with chromosomal replication origins. Mol Cell Biol. 1999; 19: 7228-7236.
3. Linder K, Gregan J, Montgomery S, Kearsey SE. Essential role of MCM proteins in premeiotic DNA replication. Mol Biol Cell. 2002; 13: 435-444.
4. Heidebrecht HJ, Buck F, Endl E, Kruse ML, Adam-Klages S, Andersen K, et al. Ki-Mcm6, a new monoclonal antibody specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. Lab Invest. 2001; 81: 1163-1165.
5. Helfenstein A, Frahm SO, Krams M, Drescher W, Parwaresch R, et al. Minichromosome maintenance protein 6 (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors. Am J Clin Pathol. 2004; 122: 912-918.
6. Labib K, Kearsey SE, Diffley JF. MCM2-7 proteins are essential components of prereplicative complexes that accumulate cooperatively in the nucleus during G1 phase and are required to establish, but not maintain, the S phase checkpoint. Mol Biol Cell. 2001; 12: 3658-3667.
7. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, et al. Minichromosome maintenance protein as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999; 5: 2121-2132.
8. Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, et al. MCM2 is an independent predictor of survival in patients with nonsmall-cell lung cancer. J Clin Oncol. 2001; 19: 4259-4266.
9. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res. 2001; 7: 2712-2718.
10. Padmanabhan V, Callas P, Philip G, Trainer TD, Beatty BG. DNA replication regulation protein MCM7 as a marker of proliferation in prostate cancer. J Clin Pathol. 2004; 57: 1057-1062.
11. Kodani I, Osaki M, Shomori K, Araki K, Goto E, Ryoke K, et al. Minichromosome maintenance protein 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2003; 32: 468-474.
12. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. Replicative MCM2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki-67 labeling index, histological grade and prognosis. Neuropathol Appl Neurobiol. 2001; 27: 305-313.
13. Wharton SB, Hibberd S, Eward KL, Crimmins D, Jellinek DA, Levy D, et al. DNA replication licensing and cell cycle kinetics of oligodendroglial tumors. Br J Cancer. 2004; 91: 262-269.
14. Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH. Aberrant expression of minichromosome maintenance protein 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barret's mucosa. Gut. 2002; 50: 373-377.
15. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Griffiths DF, Williams GH. Mcm2, Geminin, and Ki-67 definite proliferative state and rare prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005; 11: 2510-2517.
16. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol. 2004; 204: 121-130.
17. Li SS, Xue WC, Khoo US, Ngan HY, Chan KY, Tam IY, et al. Replicative MCM7 proteins as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology. 2005; 46: 307-313.
18. Guida T, Salvatore G, Faviana P, Gianinni R, Garcia-Rostan G, Provitera L, et al. Mitogenic effects of the upregulation of minichromosome maintenance (MCM) proteins in anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2005; 190: 4703-4709.
19. Chatrah P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K, et al. Aberrant expression of minichromosome maintenance protein 2 and Ki-67 in laryngeal squamous epithelial lesions. Br J Cancer. 2003; 89: 1048-1054.
20. Davidson EJ, Morris LS, Scott IS, Rushbrook SM, Bird K, Laskey RA, et al. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer. 2003; 88: 257-262.
21. Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, et al. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer. 2004; 90: 1583-1590.
22. Lukes RJ, Craver LF, Hall TC, Rappaport H, Ruben R. Report of the Nomenclature Committee. Cancer Res. 1966; 26: 1311.
23. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committe meeting. Airlie House, Virginia, November, 1997. Ann Oncol. 1999; 10: 1419-1432.
24. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29: 577-580.
25. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003; 101: 681-689.
26. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki-67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 1997; 90: 2429-2436.
27. Gerdes J, van Baarlen J, Pileri S, Schwarting R, Vanunnik JA, Stein H. Tumor cell growth fraction in Hodgkin's disease. Am J Pathol. 1987; 128: 390-393.
28. Claviez A, Tiemann M, Peters J, Kreipe H, Schneppenheim R, Parwaresch R. The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol. 1994; 68: 61-66.
29. Morgan KG, Quirke P, O'Brien CJ, Bird CC. Hodgkin's disease: a flowcytometric study. J Clin Pathol. 1988; 41: 365-369.
30. Joensuu H, Klemi PJ, Korkeila E. Prognostic value of DNA ploidy and proliferative activity in Hodgkin's disease. Am J Clin Pathol. 1988; 90: 670-673.
31. Erdkamp FL, Breed WP, Schouten HC, Janssen WC, Hoffmann JJ, Wijnen JT, et al. DNA aneuploidy and cell proliferation in relation to histology and prognosis in patients with Hodgkin's disease. Ann Oncol. 1993; 4: 75-80.
32. Bai M, Tsanou E, Agnantis NJ, Kamina S, Grepi C, Stefanaki K, et al. Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells. Mod Pathol. 2004; 17: 1338-1345.
33. Tiemann M, Claviez A, Lüders H, Zimmermann M, Schellong G, Dörffel W, et al. Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase. Mod Pathol. 2005; 18: 1440-1447.
34. Brake T, Connor JP, Petereit DG, Lambert PF. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res. 2003; 63: 8173-8180.
35. Heidebrecht HJ, Buck F, Steinmann J, Sprenger R, Wacker HH, Parwaresch R. p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood. 1997; 90: 226-233.
36. Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005; 93: 939-945.
37. Schrader C, Janssen D, Meusers P, Brittinger G, Siebmann JU, Parwaresch R, et al. Repp86: a new prognostic marker in mantle cell lymphoma. Eur J Haematol. 2005; 75: 498-504.
38. Obermann EC, Eward KL, Dogan A, Paul EA, Loddo M, Munson P, et al. DNA replication licensing in peripheral B-cell lymphoma. J Pathol. 2005; 205: 318-328.
39. Drexler HG, Gignac SM, Hoffbrand AV, Minowada J. Formation of multinucleated cells in a Hodgkin's disease-derived cell line. Int J Cancer. 1989; 43: 1083-1090.
40. Gupta RK, Lister TA, Bodmer JG. Proliferation of Reed-Sternberg cells and variants in Hodgkin's disease. Ann Oncol. 1994; 5 (suppl 1): 117-119.
41. Schlegelberger B, Weber-Matthiesen K, Himmler A, Bartels H, Somen R, Kuse R, et al. Cytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia. 1994; 8: 72-80.
42. Falzetti D, Crescenzi B, Matteuci C, Falini B, Martelli MF, van Den Berghe H, et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica. 1999; 84: 298-305.